JP2024543259A5 - - Google Patents

Info

Publication number
JP2024543259A5
JP2024543259A5 JP2024531268A JP2024531268A JP2024543259A5 JP 2024543259 A5 JP2024543259 A5 JP 2024543259A5 JP 2024531268 A JP2024531268 A JP 2024531268A JP 2024531268 A JP2024531268 A JP 2024531268A JP 2024543259 A5 JP2024543259 A5 JP 2024543259A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
naphthamide
carbamimidoyl
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2022/051405 external-priority patent/WO2023092180A1/en
Publication of JP2024543259A publication Critical patent/JP2024543259A/ja
Publication of JP2024543259A5 publication Critical patent/JP2024543259A5/ja
Pending legal-status Critical Current

Links

JP2024531268A 2021-11-24 2022-11-24 SARS-CoV-2感染を治療する方法 Pending JP2024543259A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021903789A AU2021903789A0 (en) 2021-11-24 Methods of treating sars-cov-2 infection
AU2021903789 2021-11-24
PCT/AU2022/051405 WO2023092180A1 (en) 2021-11-24 2022-11-24 Methods of treating sars-cov-2 infection

Publications (2)

Publication Number Publication Date
JP2024543259A JP2024543259A (ja) 2024-11-20
JP2024543259A5 true JP2024543259A5 (cg-RX-API-DMAC7.html) 2025-11-25

Family

ID=86538440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531268A Pending JP2024543259A (ja) 2021-11-24 2022-11-24 SARS-CoV-2感染を治療する方法

Country Status (8)

Country Link
US (1) US20250009713A1 (cg-RX-API-DMAC7.html)
EP (1) EP4436576A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024543259A (cg-RX-API-DMAC7.html)
KR (1) KR20240110039A (cg-RX-API-DMAC7.html)
CN (1) CN118574614A (cg-RX-API-DMAC7.html)
AU (1) AU2022399231A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238183A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023092180A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260100B (zh) * 2022-08-08 2023-12-12 赛诺瑞生物医药技术(无锡)有限公司 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669280B2 (en) * 2005-06-24 2014-03-11 Biotron Limited Antiviral compounds and methods
ES2614269T3 (es) * 2007-08-03 2017-05-30 Biotron Limited Procedimientos y composiciones antivíricas frente a la hepatitis C
BR112019016316A2 (pt) * 2017-02-08 2020-03-31 Biotron Limited Métodos para o tratamento da influenza
MX2022006274A (es) * 2019-11-26 2022-10-13 Biotron Ltd Metodos de tratamiento de la infeccion por vih-1.
KR20220132608A (ko) * 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 SARS CoV-2 감염증을 치료하기 위한 방법
JP7482250B2 (ja) * 2020-04-06 2024-05-13 ギリアード サイエンシーズ, インコーポレイテッド 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤

Similar Documents

Publication Publication Date Title
JP2023041862A5 (cg-RX-API-DMAC7.html)
JP2023002662A5 (cg-RX-API-DMAC7.html)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2024540183A5 (cg-RX-API-DMAC7.html)
JP2022153638A5 (cg-RX-API-DMAC7.html)
JP2022163049A5 (cg-RX-API-DMAC7.html)
JP2009535352A5 (cg-RX-API-DMAC7.html)
JP2025020117A5 (cg-RX-API-DMAC7.html)
JP2009514874A5 (cg-RX-API-DMAC7.html)
JP2021152008A5 (cg-RX-API-DMAC7.html)
JP2023175694A5 (cg-RX-API-DMAC7.html)
JP2023520323A5 (cg-RX-API-DMAC7.html)
JP2024534427A5 (cg-RX-API-DMAC7.html)
JP2024504225A5 (cg-RX-API-DMAC7.html)
JP2008533127A5 (cg-RX-API-DMAC7.html)
JP2023545372A5 (cg-RX-API-DMAC7.html)
JP2020523334A5 (cg-RX-API-DMAC7.html)
JP2016147914A (ja) 上気道の疾患およびインフルエンザ症候群を治療するための組成物
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2025508052A5 (cg-RX-API-DMAC7.html)
JP2024528731A5 (cg-RX-API-DMAC7.html)
JP2022177119A5 (cg-RX-API-DMAC7.html)
JP2013518061A5 (cg-RX-API-DMAC7.html)
JP2023517130A5 (ja) Azd1656又はその薬学的に許容される塩を含む、コロナウイルスによって引き起こされた肺炎及び/又は心筋炎の治療用組成物